Literature DB >> 22388628

Somatostatin receptor SPECT.

Giovanna Pepe1, Roy Moncayo, Emilio Bombardieri, Arturo Chiti.   

Abstract

Somatostatin is a peptide with a broad distribution in the nervous system and acts as a neurotransmitter in several organs, having a wide range of mainly inhibiting effects, such as the suppression of growth hormone release, as well as the inhibition of pancreatic and gastrointestinal hormone release. Five somatostatin receptor subtypes have been cloned and demonstrated to have an emphasized expression in all human tumours. In particular, type 2 receptors were identified as the most frequently represented on the surface of neuroendocrine tumour cells, providing the molecular basis for many clinical applications of somatostatin analogues. Towards the end of the 1980s, the in vivo demonstration of somatostatin receptors on the surface of some tumours raised interest in receptor imaging, and indeed the peptide receptor overexpression on tumour cells, as compared to normal tissues, constitutes the basis for molecular imaging of these tumours. This review intends to illustrate the development of single photon emission radiopharmaceuticals for the study of somatostatin receptors and their application in diagnostic imaging.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22388628     DOI: 10.1007/s00259-011-2019-2

Source DB:  PubMed          Journal:  Eur J Nucl Med Mol Imaging        ISSN: 1619-7070            Impact factor:   9.236


  105 in total

Review 1.  Functional-anatomical image fusion in neuroendocrine tumors.

Authors:  Orazio Schillaci
Journal:  Cancer Biother Radiopharm       Date:  2004-02       Impact factor: 3.099

2.  Radiological Protection in Biomedical Research. A report of Committee 3 adopted by the International Commission on Radiological Protection.

Authors: 
Journal:  Ann ICRP       Date:  1991

3.  [(123)I]metaiodobenzylguanidine and [(111)In]octreotide uptake in begnign and malignant pheochromocytomas.

Authors:  E van der Harst; W W de Herder ; H A Bruining; H J Bonjer; R R de Krijger ; S W Lamberts; A H van de Meiracker ; F Boomsma; T Stijnen; E P Krenning; F T Bosman; D J Kwekkeboom
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

Review 4.  Somatostatin receptors and their interest in diagnostic pathology.

Authors:  Marco Volante; Francesca Bozzalla-Cassione; Mauro Papotti
Journal:  Endocr Pathol       Date:  2004       Impact factor: 3.943

5.  99mTc-EDDA/HYNIC-TOC: a new 99mTc-labelled radiopharmaceutical for imaging somatostatin receptor-positive tumours; first clinical results and intra-patient comparison with 111In-labelled octreotide derivatives.

Authors:  C Decristoforo; S J Mather; W Cholewinski; E Donnemiller; G Riccabona; R Moncayo
Journal:  Eur J Nucl Med       Date:  2000-09

6.  Somatostatin receptor scintigraphy of carcinoid tumours using the [111In-DTPA-D-Phe1]-octreotide.

Authors:  J E Westlin; E T Janson; H Arnberg; H Ahlström; K Oberg; S Nilsson
Journal:  Acta Oncol       Date:  1993       Impact factor: 4.089

7.  Image fusion analysis of 99m Tc-HYNIC-octreotide scintigraphy and CT/MRI in patients with thyroid-associated orbitopathy: the importance of the lacrimal gland.

Authors:  Hartmann Kainz; Reto Bale; Eveline Donnemiller; Michael Gabriel; Peter Kovacs; Clemens Decristoforo; Roy Moncayo
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-06-13       Impact factor: 9.236

8.  Comparison of somatostatin receptor imaging, computed tomography and ultrasound in the clinical management of neuroendocrine gastro-entero-pancreatic tumours.

Authors:  A Chiti; S Fanti; G Savelli; A Romeo; B Bellanova; M Rodari; B J van Graafeiland; N Monetti; E Bombardieri
Journal:  Eur J Nucl Med       Date:  1998-10

9.  Comparison of radiolabeled octreotide and meta-iodobenzylguanidine (MIBG) scintigraphy in malignant pheochromocytoma.

Authors:  F Tenenbaum; J Lumbroso; M Schlumberger; A Mure; P F Plouin; B Caillou; C Parmentier
Journal:  J Nucl Med       Date:  1995-01       Impact factor: 10.057

10.  Somatostatin receptor imaging in non-functioning pituitary adenomas: value of an uptake index.

Authors:  M Duet; O Mundler; C Ajzenberg; B Berolatti; P Chedin; L Duranteau; A Warnet
Journal:  Eur J Nucl Med       Date:  1994-07
View more
  6 in total

1.  Reply to comment on Pepe et al.: Somatostatin receptor SPECT.

Authors:  Giovanna Pepe; Arturo Chiti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-11-18       Impact factor: 9.236

2.  Comment on Pepe et al.: somatostatin receptor SPECT.

Authors:  Alicja Hubalewska-Dydejczyk; Anna Sowa-Staszczak; Monika Tomaszuk
Journal:  Eur J Nucl Med Mol Imaging       Date:  2012-05-30       Impact factor: 9.236

Review 3.  Biomarkers in preclinical cancer imaging.

Authors:  Monique R Bernsen; Klazina Kooiman; Marcel Segbers; Fijs W B van Leeuwen; Marion de Jong
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-02-12       Impact factor: 9.236

4.  Early-Stage Incorporation Strategy for Regioselective Labeling of Peptides using the 2-Cyanobenzothiazole/1,2-Aminothiol Bioorthogonal Click Reaction.

Authors:  Kuo-Ting Chen; Christian Ieritano; Yann Seimbille
Journal:  ChemistryOpen       Date:  2018-02-06       Impact factor: 2.911

5.  Peptide receptor targeting in cancer: the somatostatin paradigm.

Authors:  Federica Barbieri; Adriana Bajetto; Alessandra Pattarozzi; Monica Gatti; Roberto Würth; Stefano Thellung; Alessandro Corsaro; Valentina Villa; Mario Nizzari; Tullio Florio
Journal:  Int J Pept       Date:  2013-02-07

Review 6.  Design and applications of bispecific heterodimers: molecular imaging and beyond.

Authors:  Haiming Luo; Hao Hong; Sarah P Yang; Weibo Cai
Journal:  Mol Pharm       Date:  2014-04-28       Impact factor: 4.939

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.